Navigation Links
ImmusanT's Epitope-Specific Immunotherapy for Celiac Disease Informs the Potential of Vaccines Against Other Autoimmune Diseases
Date:4/19/2013

iac Disease Center, September 22-25, 2013. The meeting will bring together the world's top scientists and physicians to discuss the most recent scientific advances in managing and treating celiac disease and gluten-related disorders. Dr. Sollid will be presenting on celiac disease during the Scientific Session, and Dr. Anderson will be presenting, "Treatments in Celiac Disease, Today and Tomorrow."

About Nexvax2®
Nexvax2 is an epitope-specific immunotherapy that combines three proprietary peptides that elicit an immune response in patients with celiac disease who carry the immune recognition gene HLA-DQ2, affecting approximately 90% of all celiac patients. In an approach similar to treatments for allergies to cats and dust mites, Nexvax2 is designed to reprogram gluten-specific T cells triggered by the patient's immune response to the protein. The goal is for Nexvax2 to restore celiac patients' immune tolerance to gluten, reduce inflammation in the nutrient-absorbing villi that line the small intestine, return the intestine to a healthy state, and allow patients to eat a normal diet.

About Celiac Disease
Celiac disease is an inherited autoimmune disorder that affects the digestive process of the small intestine. When a person with celiac disease consumes gluten, a protein found in wheat, rye and barley, the individual's immune system responds by triggering T cells to fight the offending proteins, damaging the small intestine and inhibiting the absorption of important nutrients into the body and causing long term side effects.

About ImmusanT, Inc.
ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2®, an epitope-specific immunotherapy for celiac disease, and a companion diagnosti
'/>"/>

SOURCE ImmusanT, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Cancer Immunotherapy set to enter Clinical Trials
2. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
3. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
4. Dr. Oz, Host Of The Dr. Oz Show, and Harry Zhabilov Of Immunotech Laboratories Discuss Immunotherapy Treatments For Cancer, HIV/AIDS
5. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
6. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
7. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
8. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
9. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
10. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
11. Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- According to a new market research ... Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, Genomics, ... - Global Forecast to 2020", published by MarketsandMarkets, The ... Million USD by 2020 at a CAGR of 13.9% ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... -- Today, in final recognition of the Centers for Disease ... Contacts is sharing how to keep lens cases clean.  ... do not properly care for their lens cases are ... Most contact lens wearers understand the importance of ... is sometimes overlooked.  When proper steps to clean a ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ) ... on China,s Ranibizumab Market, 2012-2019" report to their ... by CFDA to treat wet age- related macular degeneration ... Novartis, is available in the Chinese market. However, in ... the treatment of wet AMD in China ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 51-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... - IgG1 monoclonal,antibodies developed by ImClone Systems ... total presentations at the recently concluded,98th Annual ... Research,(AACR), including seven oral presentations and 37 ... the focus of,two back-to-back oral presentations leading ...
... ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis ... discussed results from two pre-clinical studies ... and,rationale for combining nab-paclitaxel (ABRAXANE(R) for ... (albumin-bound)) with VEGF inhibitor drugs like,bevacizumab ...
Cached Medicine Technology:ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 2ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 3ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 4ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 5Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... Certified Nutrition ... Nutritional Products International and InHealth media is a global sales and communications firm ... are extremely pleased to continue our business relationship with Mr. Reid Eckert, as his ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... devices for the treatment of prostate cancer, has announced the roll-out of its ... the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact ... handwritten signature. , Clinical trial sites can now use audio, video ...
(Date:8/29/2015)... ... 2015 , ... It can be uncomfortable to wear boxers ... sweat. "In order to prevent these problems, I conceived of my design," said ... UNDERGARMENT provides optimal support for a male’s crotch. It improves comfort for the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale ... costs. , “Before, a threshold of $49.00 was required to qualify for free standard ... for free standard shipping for customers regardless of the item’s selling price.” , With ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Theranostics Health announced,that it has received ... of,Health (NIH) to commercialize microdissection including Laser ... cancer diagnostics,and companion diagnostics. Under the terms ... the customary license issue royalties, minimum annual,royalties, ...
... Infections That Would ... Period, Receives $6.0 Million From Gordon and Betty Moore Foundation ... Patient Safety and Quality Improvement Efforts, WALNUT ... 39 hospitals in five San,Francisco Bay Area counties, announced today that ...
... suicide is often perceived as the result of rejection ... by teenage suicide often look back for warning signs ... tragedy. With the recent teenage suicides in Bridgend, South ... strategies. However little attention is paid to those families ...
... A new nationwide clinician survey provides the first comprehensive ... usual for nonepileptic seizures (NES), laying the groundwork for ... neuropsychiatric disorder. , There is currently no standard ... seizure but is not caused by abnormal activity in ...
... Inc. (AIS), publisher of industry-leading newsletters Health Plan,Week, ... pleased to announce,publication of "Managed Medicare and Medicaid ... and almost 30 million Medicaid recipients,enrolled in managed ... other,companies with a stake in this market place ...
... celebration of Earth Day tomorrow, medical device company announces ... ... recycling programs., ENGLEWOOD, Colo., April 21 Baxa ... for,environmental harm and support sustainable resources. As a healthcare,products ...
Cached Medicine News:Health News:NIH Grants Exclusive License to Theranostics Health 2Health News:Competing San Francisco Bay Area Hospitals Demonstrate That Collaborative Efforts Contribute to Reduced Hospital Errors and Saved Lives 2Health News:Competing San Francisco Bay Area Hospitals Demonstrate That Collaborative Efforts Contribute to Reduced Hospital Errors and Saved Lives 3Health News:Competing San Francisco Bay Area Hospitals Demonstrate That Collaborative Efforts Contribute to Reduced Hospital Errors and Saved Lives 4Health News:Competing San Francisco Bay Area Hospitals Demonstrate That Collaborative Efforts Contribute to Reduced Hospital Errors and Saved Lives 5Health News:Teenage suicides: Study advocates greater family support 2Health News:Survey offers first-ever look at treatment practices for nonepileptic seizures 2Health News:New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits 2Health News:Baxa Environmental Program Nets Significant Results 2Health News:Baxa Environmental Program Nets Significant Results 3